Menu
 
Research menu
Jump to menu

Publications:  Prof Gareth Sanger

Sanger G, Andrews P(2020). Emesis. In: Offermanns S., Rosenthal W. (eds) Encyclopedia of Molecular Pharmacology. Springer, Cham
10.1007/978-3-030-21573-6_161-1
Straface M, Makwana R, Palmer A, Rombolà L, Aleong JC, Morrone LA, Sanger GJ(2020). Inhibition of neuromuscular contractions of human and rat colon by bergamot essential oil and linalool: Evidence to support a therapeutic action. Nutrients vol. 12, (5)
10.3390/nu12051381
Cibert-Goton V, Kung VWS, McGuire C, Hockley JRF, Tranter MM, Dogra H, Belai A, Blackshaw LA et al.(2020). Functional and anatomical deficits in visceral nociception with age: a mechanism of silent appendicitis in the elderly?. Pain vol. 161, (4) 773-786.
10.1097/j.pain.0000000000001764
https://qmro.qmul.ac.uk/xmlui/handle/123456789/65664
Choudhry N, Scott F, Edgar M, Sanger GJ, Kelly P(2020). Reversal of Pathogen-Induced Barrier Defects in Intestinal Epithelial Cells by Contra-pathogenicity Agents. Digestive Diseases and Sciences
10.1007/s10620-020-06121-9
https://qmro.qmul.ac.uk/xmlui/handle/123456789/62779
Straface M, Makwana R, Rombola L, Chinaleong J, Morrone LA, Sanger GJ (2019). Bergamot essential oil and its constituent linalool, inhibit cholinergically-mediated contractions of human and rat isolated colon. NEUROGASTROENTEROLOGY AND MOTILITY. vol. 31,
https://qmro.qmul.ac.uk/xmlui/handle/123456789/64514
Palmer A, Straface M, Chin-Aleong J, Knowles C, Sanger GJ (2019). Isolation and culture of primary myenteric neurons and glial cells from human colon: The effects of different concentrations of nerve growth factor. NEUROGASTROENTEROLOGY AND MOTILITY. vol. 31,
Makwana R, Elahi S, Adebibe M, Loy J, Sanger GJ (2019). Low concentrations of arginine vasopressin (AVP) act at V1A receptors in human stomach to increase frequency and amplitude of spontaneous rhythmic contractions: Role in nausea. NEUROGASTROENTEROLOGY AND MOTILITY. vol. 31,
Scott F, Elahi S, Adebibe M, Parampalli U, Mannur K, Góralczyk A, Sanger GJ(2019). Farnesoid X receptor ‐ a molecular predictor of weight loss after vertical sleeve gastrectomy?. Obesity Science & Practice vol. 5, (3) 273-280.
10.1002/osp4.337
https://qmro.qmul.ac.uk/xmlui/handle/123456789/56398
Ruffle JK, Patel A, Giampietro V, Howard MA, Sanger GJ, Andrews PLR, Williams SCR, Aziz Q et al.(2019). Functional brain networks and neuroanatomy underpinning nausea severity can predict nausea susceptibility using machine learning. Journal of Physiology vol. 597, (6) 1517-1529.
10.1113/JP277474
https://qmro.qmul.ac.uk/xmlui/handle/123456789/54756
SANGER GJ, BROAD J, KUNG V, Palmer A, ELAHI S, Karami A, Darreh-Shori T, Ahmed S et al.(2018). Changes in neuromuscular structure and functions of human colon during ageing are region-dependent. Gut
10.1136/gutjnl-2018-316279
https://qmro.qmul.ac.uk/xmlui/handle/123456789/44826
SANGER GJ, Andrews PLR(2018). A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research. Front. Pharmacol. 9:913. vol. 9, Article 913,
10.3389/fphar.2018.00913
https://qmro.qmul.ac.uk/xmlui/handle/123456789/44618
Liszt KI, Ley JP, Lieder B, Behrens M, Stöger V, Reiner A, Hochkogler CM, Köck E et al.(2017). Caffeine induces gastric acid secretion via bitter taste signaling in gastric parietal cells. Proceedings of the National Academy of Sciences vol. 114, (30) E6260-E6269.
10.1073/pnas.1703728114
https://qmro.qmul.ac.uk/xmlui/handle/123456789/59116
Sanger GJ, Pasricha PJ(2017). Investigational drug therapies for the treatment of gastroparesis. Expert Opin Investig Drugs vol. 26, (3) 331-342.
10.1080/13543784.2017.1288214
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55254
Sanger GJ, Broad J, Callaghan B, Furness JB(2016). Ghrelin and Motilin Control Systems in GI Physiology and Therapeutics. vol. 239, SpringerLink
https://qmro.qmul.ac.uk/xmlui/handle/123456789/56731
McGuire C, Boundouki G, Hockley JR, Reed D, Cibert-Goton V, Peiris M, Kung V, Broad J et al.(2016). Ex vivo study of human visceral nociceptors. GUT Article 27654583, 1-11.
10.1136/gutjnl-2016-311629
https://qmro.qmul.ac.uk/xmlui/handle/123456789/15894
Broad J, Maurel D, Kung VWS, Hicks GA, Schemann M, Barnes MR, Kenakin TP, Granier S et al.(2016). Human native kappa opioid receptor functions not predicted by recombinant receptors: Implications for drug design. Scientific Reports vol. 6,
10.1038/srep30797
https://qmro.qmul.ac.uk/xmlui/handle/123456789/15914
Sanger GJ(2016). Chronic constipation: improved understanding offers a new therapeutic approach. J Physiol vol. 594, (15) 4085-4087.
10.1113/JP272560
https://qmro.qmul.ac.uk/xmlui/handle/123456789/13816
Broad J, Kung V, Karami A, Darreh-Shori T, Knowles C, Sanger GJ (2016). Region-specific increase in colonic function of choline acetyltransferase in the elderly. NEUROGASTROENTEROLOGY AND MOTILITY. Conference: Neurogastro Motility vol. 28, 102-102.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58834
Hellström PM, Tack J, Johnson LV, Hacquoil K, Barton ME, Richards DB, Alpers DH, Sanger GJ et al.(2016). The pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying. British Journal of Pharmacology vol. 173, (11) 1768-1777.
10.1111/bph.13475
Broad J, Takahashi N, Tajimi M, Sudo M, Góralczyk A, Parampalli U, Mannur K, Yamamoto T et al.(2016). RQ-00201894: A motilin receptor agonist causing long-lasting facilitation of human gastric cholinergically-mediated contractions. J Pharmacol Sci vol. 130, (2) 60-65.
10.1016/j.jphs.2015.11.004
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11316
Sanger GJ, Furness JB(2016). Ghrelin and motilin receptors as drug targets for gastrointestinal disorders. Nat Rev Gastroenterol Hepatol vol. 13, (1) 38-48.
10.1038/nrgastro.2015.163
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11317
Kung V, Broad J, Machesney M, THAHA MA, Knowles CH, Sanger G (2015). Preoperative chemotherapy does not appear to have short-term effects on human rectal neuromuscular functions. Gut. Conference: Digestive Disorders Federation 2015 (London, UK) from: 22/06/2015 to: 26/06/2015, vol. Suppl 1, A584-A584.
10.1136/gutjnl-2015-309861.1152
Broad J, Callaghan B, Sanger GJ, Brock JA, Furness JB(2015). Analysis of the ghrelin receptor-independent vascular actions of ulimorelin. Eur J Pharmacol vol. 752, 34-39.
10.1016/j.ejphar.2015.02.005
Farmer AD, Ban VF, Coen SJ, Sanger GJ, Barker GJ, Gresty MA, Giampietro VP, Williams SC et al.(2015). Visually induced nausea causes characteristic changes in cerebral, autonomic and endocrine function in humans. J Physiol vol. 593, (5) 1183-1196.
10.1113/jphysiol.2014.284240
https://qmro.qmul.ac.uk/xmlui/handle/123456789/6727
Broad J, Hughes F, Chin-Aleong J, Sifrim D, Sanger GJ(2014). Regionally dependent neuromuscular functions of motilin and 5-HT₄ receptors in human isolated esophageal body and gastric fundus. Neurogastroenterol Motil vol. 26, (9) 1311-1322.
10.1111/nmo.12394
Broad J, Góralczyk A, Mannur K, Dukes GE, Sanger GJ(2014). Drugs acting at 5-HT4 , D2 , motilin, and ghrelin receptors differ markedly in how they affect neuromuscular functions in human isolated stomach. Neurogastroenterol Motil vol. 26, (6) 851-861.
10.1111/nmo.12338
Kung VWS, Broad J, Sanger GJ, Knowles CH (2014). Gender- and regionally-specific decline in colonic neuromuscular activity with advanced age. BRITISH JOURNAL OF SURGERY. vol. 101, 3-3.
Sanger GJ(2014). The relationship between symptom improvement and gastric emptying in the treatment of gastroparesis: remember the pharmacology. Am J Gastroenterol vol. 109, (3) 444-445.
10.1038/ajg.2013.432
Sanger GJ(2014). Ghrelin and motilin receptor agonists: time to introduce bias into drug design. Neurogastroenterol Motil vol. 26, (2) 149-155.
10.1111/nmo.12300
Andrews PLR, Sanger GJ(2014). Nausea and the quest for the perfect anti-emetic. EUROPEAN JOURNAL OF PHARMACOLOGY vol. 722, 108-121.
10.1016/j.ejphar.2013.09.072
Andrews PLR, Sanger GJ(2014). Nausea and the quest for the perfect anti-emetic. Eur J Pharmacol vol. 722, 108-121.
10.1016/j.ejphar.2013.09.072
Sanger GJ(2013). Ghrelin and motilin receptor agonists: a long and winding misconception. Neurogastroenterol Motil vol. 25, (12)
10.1111/nmo.12241
Sanger GJ, Wang Y, Hobson A, Broad J(2013). Motilin: towards a new understanding of the gastrointestinal neuropharmacology and therapeutic use of motilin receptor agonists. Br J Pharmacol vol. 170, (7) 1323-1332.
10.1111/bph.12075
Broad J, Kung VWS, Boundouki G, Aziz Q, De Maeyer JH, Knowles CH, Sanger GJ(2013). Cholinergic interactions between donepezil and prucalopride in human colon: potential to treat severe intestinal dysmotility. Br J Pharmacol vol. 170, (6) 1253-1261.
10.1111/bph.12397
Sanger GJ, Broad J, Andrews PLR(2013). The relationship between gastric motility and nausea: gastric prokinetic agents as treatments. Eur J Pharmacol vol. 715, (1-3) 10-14.
10.1016/j.ejphar.2013.06.031
Broad J, Sanger GJ(2013). The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin. Br J Pharmacol vol. 168, (8) 1859-1867.
10.1111/bph.12077
Javid FA, Bulmer DC, Broad J, Aziz Q, Dukes GE, Sanger GJ(2013). Anti-emetic and emetic effects of erythromycin in Suncus murinus: role of vagal nerve activation, gastric motility stimulation and motilin receptors. Eur J Pharmacol vol. 699, (1-3) 48-54.
10.1016/j.ejphar.2012.11.035
Sanger GJ(2013). Novel insights which may translate into treatments for irritable bowel syndrome. FRONTIERS IN PHARMACOLOGY vol. 4, Article ARTN 160,
10.3389/fphar.2013.00160
Sanger GJ, Broad J, Kung V, Knowles CH(2013). Translational neuropharmacology: the use of human isolated gastrointestinal tissues. Br J Pharmacol vol. 168, (1) 28-43.
10.1111/j.1476-5381.2012.02198.x
Sanger GJ(2012). Motilin receptor neuropharmacology: revised understanding. Curr Opin Pharmacol vol. 12, (6) 641-646.
10.1016/j.coph.2012.07.012
Sanger GJ(2012). New target profiling for gastrointestinal disorders: where are we going?. Curr Opin Pharmacol vol. 12, (6) 629-631.
10.1016/j.coph.2012.10.006
Broad J, Mukherjee S, Samadi M, Martin JE, Dukes GE, Sanger GJ(2012). Regional- and agonist-dependent facilitation of human neurogastrointestinal functions by motilin receptor agonists. Br J Pharmacol vol. 167, (4) 763-774.
10.1111/j.1476-5381.2012.02009.x
Ng KS, Andrews P, Chua YC, Ban VF, Gresty M, Coen SJ, Sanger GJ, Williams SC et al.(2012). Psychophysiological markers and the brain processing of nausea in healthy humans using a novel virtual reality video. NEUROGASTROENTEROLOGY AND MOTILITY vol. 24, 39-40.
Ng KS, Coen SJ, Chua YC, Ban VF, Gresty MA, Sanger GJ, Williams SC, Barker GJ et al.(2012). STUDIES OF THE PSYCHOPHYSIOLOGICAL MARKERS AND THE BRAIN PROCESSING OF NAUSEA IN HEALTHY HUMANS USING A NOVEL VIRTUAL REALITY VIDEO. GUT vol. 61, A317-A318.
10.1136/gutjnl-2012-302514d.51
Broad J, Andrews PL, Sanger GJ(2012). VASOPRESSIN CONTRACTS HUMAN ISOLATED STOMACH MUSCLE: POSSIBLE ROLE IN NAUSEA?. GUT vol. 61, A297-A298.
10.1136/gutjnl-2012-302514d.3
Sung EZ, Arasaradnam RP, Jarvie EM, James S, Goodyear SJ, Borman RA, Snead D, SANGER GJ et al.(2012). Effects of neo-adjuvant chemotherapy for oesophago-gastric cancer on neuro-muscular gastric function. Mol Biol Rep vol. 39, (12) 9989-9994.
10.1007/s11033-012-1866-7
Leming S, Broad J, Cozens SJ, Otterson M, Winchester W, Lee K, Dukes GE, Sanger GJ(2011). GSK962040: a small molecule motilin receptor agonist which increases gastrointestinal motility in conscious dogs. Neurogastroenterol Motil vol. 23, (10) 958-e410.
10.1111/j.1365-2982.2011.01770.x
Sanger GJ, Holbrook JD, Andrews PLR(2011). The translational value of rodent gastrointestinal functions: a cautionary tale. Trends Pharmacol Sci vol. 32, (7) 402-409.
10.1016/j.tips.2011.03.009
Sanger GJ, Broad J, Alpers DH(2011). Translation of Motilin and Ghrelin Receptor Agonists into Drugs for Gastrointestinal Disorders. Peptide Drug Discovery and Development. Translational Research in Academia and Industry, Editors: Castanho, MARB, Santos, NC, Wiley VCH
Sanger GJ, Chang L, Bountra C, Houghton LA(2010). Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders. Therap Adv Gastroenterol vol. 3, (5) 291-305.
10.1177/1756283X10369922
Broad J, Leming S, Matthews KL, Briggs M, Otterson M, Winchester W, Cozens SJ, Dukes GE et al. (2010). GSK962040: a small molecule motilin receptor agonist which increases gastrointestinal (GI) motility in dogs. NEUROGASTROENTEROLOGY AND MOTILITY. vol. 22, 84-84.
Falken Y, Hellstrom PM, Sanger GJ, Dewit O, Dukes G, Gryback P, Holst JJ, Naslund E(2010). Actions of prolonged ghrelin infusion on gastrointestinal transit and glucose homeostasis in humans. NEUROGASTROENT MOTIL vol. 22, (6) e192-e200.
10.1111/j.1365-2982.2009.01463.x
Broad J, Boundouki G, Knowles CH, Sanger GJ (2010). CHARACTERISATION OF MOTOR NERVE RESPONSES TO ELECTRICAL FIELD STIMULATION IN HUMAN ISOLATED COLON. GUT. vol. 59, A140-A140.
10.1136/gut.2009.209049d
Sanger GJ, Chang L, Bountra C, Houghton L(2010). Challenges and Prospects for Pharmacotherapy in Functional Gastrointestinal Disorders. Ther Adv Gastroenterol vol. 3, (5) 291-305.
10.1177/1756283X10369922
Broad J, Mukherjee S, Boundouki G, Dukes GE, Sanger GJ (2010). Different abilities of [Nle13]-motilin and the motilin receptor agonist GSK962040 to facilitate cholinergic and nitrergic activity in human isolated stomach. Neurogastroenterol Motil. vol. 22 (S1),
Ferens DM, Yin L, Bron R, Hunne B, Ohashi-Doi K, Kitchener PD, Sanger GJ, Witherington J et al.(2010). Functional and in situ hybridisation evidence that preganglionic sympathetic vasoconstrictor neurons express ghrelin receptors. Neuroscience vol. 166, (2) 671-679.
10.1016/j.neuroscience.2010.01.001
Broad J, Leming S, Matthews KL, Briggs M, Otterson M, Winchester W, Cozens SJ, Dukes GE et al. (2010). GSK962040: a small molecule motilin receptor agonist which increases gastrointestinal (GI) motility in dogs. Neurogastroenterol Motil. vol. 23, 958-e410.
10.1111/j.1365-2982.2011.01770.x
Sanger GJ(2010). Gastrointestinal pharmacology: challenges ahead. Front Pharm vol. 1, 4-4.
10.3389/fphar.2010.00004
https://qmro.qmul.ac.uk/xmlui/handle/123456789/13578
Ng K, Chua Y, Gresty M, Marreddy U, Williams S, Barker G, Andrews P, Sanger G et al. (2010). Identification of psychophysiological biomarkers of nausea using a novel visual induction method. Gut. vol. 59 suppl 1,
10.1136/gut.2009.208975t
Sanger GJ, Hellström PM, Näslund E(2010). The hungry stomach: physiology, disease, and drug development opportunities. Front Pharmacol vol. 1,
10.3389/fphar.2010.00145
Sanger GJ(2009). Translating 5-HT receptor pharmacology. Neurogastroenterol Motil vol. 21, (12) 1235-1238.
10.1111/j.1365-2982.2009.01425.x
Holbrook JD, Gill CH, Zebda N, Spencer JP, Leyland R, Rance KH, Trinh H, Balmer G et al.(2009). Characterisation of 5-HT3c, 5-HT3d and 5-HT3e receptor subunits: evolution, distribution and function. J Neurochem vol. 108, (2) 384-396.
SANGER GJ, Westaway SM, Brown SL, Fell SCM, Johnson CM, MacPherson DT, Mitchell DJ, Myatt JW et al.(2009). Discovery of N-(3-Fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040): The first small molecule motilin receptor agonist clinical candidate. J Med Chem vol. 52, 1180-1189.
SANGER GJ, Westaway SM, Barnes AA, Macpherson DT, Muir AI, Jarvie EM, Bolton VN, Cellek S et al.(2009). GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. Neurogastroenterology and Motility vol. 21, 657-666.
Bassil AK, Taylor CM, Bolton VJN, Grey KM, Brown JD, Cutler L, Summerfield SG, Bruton G et al.(2009). Inhibition of colonic motility and defecation by RS-127445 suggests an involvement of the 5-HT2B receptor in rodent large bowel physiology. Br J Pharmacol vol. 158, (1) 252-258.
Bailey JM, Scott JS, Basilla JB, Bolton VJ, Boyfield I, Evans DG, Fleury E, Heightman TD et al.(2009). The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor. Bioorg Med Chem Lett vol. 19, (22) 6452-6458.
Westaway SM, Sanger GJ(2009). The identification and rationale for drugs which act at the motilin receptor. Progress in Medicinal Chemistry vol. 48, 31-80.
Bassil AK, Borman RA, Jarvie EM, McArthur-Wilson RJ, Thangiah R, Sung EZ, Lee K, Sanger GJ(2008). Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Pharmacol vol. 154, 126-135.
Sanger GJ, Alpers DH(2008). Development of drugs for gastrointestinal motor disorders: translating science to clinical need. Neurogastroenterol Motil vol. 20, 177-184.
Sanger GJ, Lee K(2008). Hormones of the gut-brain axis as targets for the treatment of upper gastrointestinal disorders. NATURE REVIEWS DRUG DISCOVERY vol. 7, 242-254.
Olsson C, Holbrook JD, Bompadre G, Jönsson E, Hoyle C, Sanger GJ, Holmgren S, Andrews PLR(2008). Identification of genes for ghrelin and motilin receptors and a novel related gene in fish, and stimulation of intestinal motility in zebrafish (Danio rerio) by ghrelin and motilin. Gen Comparative Endocrinol vol. 155, 217-226.
Witherington J, Abberley L, Briggs MA, Collis K, Dean DK, Gaiba A, King PN, Kraus H et al.(2008). Potent achiral agonists of the growth hormone secretatgogue (ghrelin) receptor. Part 2 – Lead Optimisation. Bioorg Med Chem Lett vol. 18, 2203-2205.
Cellek S, Thangiah R, Jarvie EM, Vivekanandan S, Lalude O, Sanger GJ(2008). Synergy between 5-HT4 receptor activation and acetylcholinesterase inhibition in human colon and rat forestomach. Neurogastroenterol Motil vol. 20, 539-545.
Sanger GJ, Tuladhar BR, Brown J, Aziz E, Sivakumar D, Furness JB(2007). Modulation of peristalsis by NK3 receptor antagonism in guinea-pig isolated ileum is revealed as intraluminal pressure is raised. Autonom Autocoid Pharmacol vol. 27, 105-111.
Sanger GJ, Tuladhar BR, Bueno L, Furness JB(2006). Defensive and pathological functions of the gastrointestinal NK3 receptor. Vascular Pharmacology vol. 45, 215-220.
SANGER GJ(1987). Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis. British Journal of Cancer vol. 56, 159-162.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/54856
SANGER GJ, Miner WD(1986). Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. British Journal of Pharmacology vol. 88, 497-499.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/54854
Return to top